NCT06952660 (ClinicalTrials.gov Identifier: NCT06952660) is a Phase 4 clinical trial focused on evaluating ocular assessments in adult female patients with recurrent or metastatic cervical cancer who have experienced disease progression on or after chemotherapy. The study examines the use of Tivdak® (tisotumab vedotin-tftv), an approved antibody-drug conjugate administered intravenously, as part of ongoing post-marketing surveillance. This multicenter effort aims to gather data on ocular safety in real-world settings..

“OSF HealthCare is deeply committed to advancing care for patients with gynecologic malignancies, including the significant challenges of recurrent or metastatic cervical cancer,” said Dr. Michelle Rowland, Translational Researcher and Gynecologic Oncologist, OSF HealthCare Cancer Institute. “Clinical trials like this one offer eligible patients the opportunity to receive established therapies under exceptionally close medical supervision, while directly contributing to the generation of high-quality safety data that can improve treatment approaches for future patients and help accelerate meaningful progress in the field.”

All clinical research at OSF HealthCare is subject to thorough ethical review and continuous oversight to prioritize participant safety and integrity.

Donors and researchers interested in supporting or collaborating on oncology initiatives at OSF HealthCare are invited to connect with our team by calling (844) 673-4467 or emailing sfmc.clinicaltrials@osfhealthcare.org.